Springworks Therapeutics Inc. has closed a $125 million series B preferred stock financing, energizing its two late-stage rare disease oncology programs, nirogacestat (PF-03084014), a gamma-secretase inhibitor for treating desmoid tumors, and PD-0325901, an MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas.